Category: AbbVie

The Accept Phase Ib/II Single Arm Study

Oral and Poster Abstracts 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III Research, clinical trials, Lymphomas, Clinical Research, Combination therapy, Diseases, aggressive lymphoma, Therapies, Lymphoid Malignancies Andrew J Davies, BSc, BM, FRCP, PhD1,2*, Josh Caddy, BSc3*, Katy McLaughlin, BSc3*, Christopher Wignall, MSc3*, Robert…

Continue Reading The Accept Phase Ib/II Single Arm Study

Applications for Epcoritamab Submitted to FDA and EMA in Relapsed/Refractory LBCL/DLBCL

Patients with relapsed/refractory large B-cell lymphoma may benefit from epcoritamab, the biologics license applications of which were submitted to the FDA. A biologics license application for subcutaneous epcoritamab (DuoBody-CD3xCD20) was submitted to the FDA for patients with relapsed/refractory large B-cell lymphoma (LBCL) following 2 or more lines of systemic therapy…

Continue Reading Applications for Epcoritamab Submitted to FDA and EMA in Relapsed/Refractory LBCL/DLBCL

Intellia: Slim Hopes Of Near-Term Commercial Revenue, Bearish

liulolo/iStock via Getty Images Investment Thesis If you had invested in the CRISPR / Cas9 gene editing pioneer Intellia Therapeutics (NASDAQ:NTLA) five years ago, you would likely be well satisfied with your return to date – a ~285% return on your investment – although you may also feel that it…

Continue Reading Intellia: Slim Hopes Of Near-Term Commercial Revenue, Bearish

Beam Therapeutics Stock: A Leader in Gene Editing Tech?

Don’t invest in stories. Don’t invest in a company before they have meaningful revenues. Don’t invest in drug developers that have a great deal of regulatory risk. These are all rules we need to break if we want exposure to a technology that allows mankind to start playing with the…

Continue Reading Beam Therapeutics Stock: A Leader in Gene Editing Tech?

Roche (RHHBY) Gets EC Approval for Polivy Combination in DLBCL – May 26, 2022

Roche (RHHBY Quick QuoteRHHBY – Free Report) recently announced that the European Commission (“EC”) has granted approval to lymphoma drug Polivy (polatuzumab vedotin) in combination with MabThera (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Polivy is…

Continue Reading Roche (RHHBY) Gets EC Approval for Polivy Combination in DLBCL – May 26, 2022